343 related articles for article (PubMed ID: 27237360)
1. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.
Schwartz LH; Seymour L; Litière S; Ford R; Gwyther S; Mandrekar S; Shankar L; Bogaerts J; Chen A; Dancey J; Hayes W; Hodi FS; Hoekstra OS; Huang EP; Lin N; Liu Y; Therasse P; Wolchok JD; de Vries E
Eur J Cancer; 2016 Jul; 62():138-45. PubMed ID: 27237360
[TBL] [Abstract][Full Text] [Related]
2. RECIST - learning from the past to build the future.
Litière S; Collette S; de Vries EG; Seymour L; Bogaerts J
Nat Rev Clin Oncol; 2017 Mar; 14(3):187-192. PubMed ID: 27995946
[TBL] [Abstract][Full Text] [Related]
3. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA; Therasse P; Bogaerts J; Schwartz LH; Sargent D; Ford R; Dancey J; Arbuck S; Gwyther S; Mooney M; Rubinstein L; Shankar L; Dodd L; Kaplan R; Lacombe D; Verweij J
Eur J Cancer; 2009 Jan; 45(2):228-47. PubMed ID: 19097774
[TBL] [Abstract][Full Text] [Related]
4. RECIST 1.1-Update and clarification: From the RECIST committee.
Schwartz LH; Litière S; de Vries E; Ford R; Gwyther S; Mandrekar S; Shankar L; Bogaerts J; Chen A; Dancey J; Hayes W; Hodi FS; Hoekstra OS; Huang EP; Lin N; Liu Y; Therasse P; Wolchok JD; Seymour L
Eur J Cancer; 2016 Jul; 62():132-7. PubMed ID: 27189322
[TBL] [Abstract][Full Text] [Related]
5. RECIST revisited: a review of validation studies on tumour assessment.
Therasse P; Eisenhauer EA; Verweij J
Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and the role of imaging.
Carter BW; Bhosale PR; Yang WT
Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
8. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
9. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.
Goebel J; Hoischen J; Gramsch C; Schemuth HP; Hoffmann AC; Umutlu L; Nassenstein K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2527-2533. PubMed ID: 28825135
[TBL] [Abstract][Full Text] [Related]
10. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
Houdek Š; Büchler T; Kindlová E
Klin Onkol; 2017; 30(Supplementum3):32-39. PubMed ID: 29239190
[TBL] [Abstract][Full Text] [Related]
12. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community.
Liu Y; Litière S; de Vries EG; Sargent D; Shankar L; Bogaerts J; Seymour L
Eur J Cancer; 2014 Jan; 50(2):260-6. PubMed ID: 24239447
[TBL] [Abstract][Full Text] [Related]
13. Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology?
McHugh K; Kao S
Br J Radiol; 2003 Jul; 76(907):433-6. PubMed ID: 12857700
[No Abstract] [Full Text] [Related]
14. Volume-based response evaluation with consensual lesion selection: a pilot study by using cloud solutions and comparison to RECIST 1.1.
Oubel E; Bonnard E; Sueoka-Aragane N; Kobayashi N; Charbonnier C; Yamamichi J; Mizobe H; Kimura S
Acad Radiol; 2015 Feb; 22(2):217-25. PubMed ID: 25488429
[TBL] [Abstract][Full Text] [Related]
15. QA procedures for multimodality preclinical tumor drug response testing.
Lee YC; Goins BA; Fullerton GD
Med Phys; 2010 Sep; 37(9):4806-16. PubMed ID: 20964200
[TBL] [Abstract][Full Text] [Related]
16. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Seymour L; Bogaerts J; Perrone A; Ford R; Schwartz LH; Mandrekar S; Lin NU; Litière S; Dancey J; Chen A; Hodi FS; Therasse P; Hoekstra OS; Shankar LK; Wolchok JD; Ballinger M; Caramella C; de Vries EGE;
Lancet Oncol; 2017 Mar; 18(3):e143-e152. PubMed ID: 28271869
[TBL] [Abstract][Full Text] [Related]
17. Imaging response assessment for oncology: An algorithmic approach.
Ruchalski K; Dewan R; Sai V; McIntosh LJ; Braschi-Amirfarzan M
Eur J Radiol Open; 2022; 9():100426. PubMed ID: 35693043
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
Min SJ; Jang HJ; Kim JH
Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
[TBL] [Abstract][Full Text] [Related]
19. Improving accuracy in reporting CT scans of oncology patients: assessing the effect of education and feedback interventions on the application of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Andoh H; McNulty NJ; Lewis PJ
Acad Radiol; 2013 Mar; 20(3):351-7. PubMed ID: 23452481
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?
Mattonen SA; Ward AD; Palma DA
Br J Radiol; 2016 Sep; 89(1065):20160113. PubMed ID: 27245137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
